Leap Therapeutics Inc [NASDAQ: LPTX] price surged by 52419953 percent to reach at $2159999.62.
The one-year LPTX stock forecast points to a potential downside of -39272627.27. The average equity rating for LPTX stock is currently 3.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Leap Therapeutics Inc [LPTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LPTX shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LPTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Leap Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 29, 2025. The new note on the price target was released on January 29, 2025, representing the official price target for Leap Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Rodman & Renshaw analysts kept a Buy rating on LPTX stock.
The Price to Book ratio for the last quarter was 0.61, with the Price to Cash per share for the same quarter was set at 0.79.
LPTX Stock Performance Analysis:
Leap Therapeutics Inc [LPTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.62. With this latest performance, LPTX shares dropped by -14.50% in over the last four-week period, additionally sinking by -90.06% over the last 6 months – not to mention a drop of -89.25% in the past year of trading.
Insight into Leap Therapeutics Inc Fundamentals:
Return on Equity for this stock declined to -149.01%, with Return on Assets sitting at -149.01%.
LPTX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LPTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Leap Therapeutics Inc go to 32.77%.
Leap Therapeutics Inc [LPTX] Institutonal Ownership Details
The top three institutional holders of LPTX stocks are: BALYASNY ASSET MANAGEMENT L.P. with ownership of 3.1 million shares, which is approximately 7.9238%. SAMSARA BIOCAPITAL, LLC, holding 2.44 million shares of the stock with an approximate value of $$4.79 million in LPTX stocks shares; and SAMSARA BIOCAPITAL, LLC, currently with $$2.55 million in LPTX stock with ownership which is approximately 3.3229%.
